Trevi Therapeutics, Inc. (TRVI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Trevi Therapeutics, Inc. (TRVI) Healthcare & Pipeline Overview

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio, an oral extended-release formulation of nalbuphine. Currently in Phase IIb/III clinical trials, Haduvio targets chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis, positioning Trevi in the competitive biotechnology landscape.

What Is the Investment Thesis for TRVI?

Trevi Therapeutics presents a focused investment opportunity centered on the development and potential commercialization of Haduvio. The drug's progress through Phase IIb/III clinical trials for chronic pruritus and chronic cough in IPF represents a significant value driver. Successful trial outcomes and subsequent regulatory approvals could lead to substantial revenue generation, given the unmet medical needs in these areas. The company's market capitalization of $2.26B reflects investor expectations regarding Haduvio's potential. Key catalysts include the release of clinical trial data and potential partnerships for commercialization. However, the investment is subject to risks associated with clinical trial failures, regulatory hurdles, and competition from existing or emerging therapies. The company's reliance on a single lead product also concentrates risk. Monitoring clinical trial results and regulatory developments is crucial for assessing the investment's viability.

Based on FMP financials and quantitative analysis

TRVI Key Highlights

Haduvio is in Phase IIb/III clinical trials for chronic pruritus, indicating advanced stage development.

• Haduvio is also in Phase IIb/III clinical trials for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), expanding its potential market.
• Market capitalization of $2.26B reflects investor valuation of Trevi's pipeline and potential.
• The company has a license agreement with Endo Pharmaceuticals Inc., providing access to nalbuphine hydrochloride for product development.
• Trevi Therapeutics has 31 employees, indicating a focused and lean operational structure.

Who Are TRVI's Competitors?

TRVI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TRVI's Key Strengths?

Lead product, Haduvio, in Phase IIb/III clinical trials.

• Focus on unmet medical needs in chronic pruritus and chronic cough in IPF.
• License agreement with Endo Pharmaceuticals Inc. for nalbuphine hydrochloride.
• Experienced management team with expertise in drug development.

What Are TRVI's Weaknesses?

Reliance on a single lead product, Haduvio.

• Clinical-stage company with no currently marketed products.
• High cash burn rate associated with clinical trials.
• Dependence on successful clinical trial outcomes and regulatory approvals.

What Could Drive TRVI Stock Higher?

Announcement of Phase IIb/III clinical trial results for Haduvio in chronic pruritus.

• Announcement of Phase IIb/III clinical trial results for Haduvio in chronic cough in patients with idiopathic pulmonary fibrosis (IPF).
• Potential FDA review and approval of Haduvio for chronic pruritus.
• Potential FDA review and approval of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF).

What Are the Key Risks for TRVI?

Negative return on equity (-23.6%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure of Phase IIb/III clinical trials for Haduvio.
• Regulatory rejection of Haduvio by the FDA.
• Competition from other companies developing treatments for chronic pruritus and chronic cough in IPF.
• Dependence on successful commercialization of Haduvio for revenue generation.
• High cash burn rate associated with clinical development activities.

What Are the Growth Opportunities for TRVI?

• Successful completion of Phase III clinical trials for Haduvio in chronic pruritus represents a significant growth opportunity. Positive trial results could lead to regulatory approval and commercialization, addressing a market with substantial unmet needs. The timeline for this growth opportunity is dependent on the progression and outcome of the ongoing clinical trials.
• The development and commercialization of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) presents another substantial growth avenue. IPF is a progressive and debilitating lung disease with limited treatment options, creating a high demand for effective therapies. Success in this indication could significantly expand Trevi's market reach and revenue potential. The timeline for this growth opportunity is aligned with the clinical trial and regulatory approval process for Haduvio in IPF.
• Expansion of the Haduvio pipeline to address other neurologically mediated conditions represents a long-term growth opportunity. By leveraging the therapeutic potential of nalbuphine in different indications, Trevi Therapeutics can diversify its product portfolio and reduce its reliance on a single lead product. This strategy could involve preclinical and clinical development of new formulations or indications for nalbuphine. The timeline for this growth opportunity extends beyond the current clinical trials for chronic pruritus and chronic cough in IPF.
• Strategic partnerships with pharmaceutical companies for the commercialization of Haduvio can accelerate market penetration and maximize revenue generation. Collaborating with established players in the pharmaceutical industry can provide Trevi Therapeutics with access to extensive distribution networks and marketing expertise. This approach can enhance the commercial success of Haduvio and generate significant value for the company. The timeline for this growth opportunity is contingent on securing suitable partnership agreements.
• Exploring new formulations or delivery methods for nalbuphine, such as transdermal patches or injectable solutions, could enhance patient convenience and improve therapeutic outcomes. This innovation could differentiate Haduvio from existing oral formulations and expand its market appeal. Investing in research and development to explore these alternative formulations represents a long-term growth opportunity for Trevi Therapeutics. The timeline for this growth opportunity is dependent on the success of preclinical and clinical studies evaluating these new formulations.

What Threats Does TRVI Face?

• Clinical trial failures or delays.
• Regulatory hurdles and rejection of Haduvio.
• Competition from existing or emerging therapies.
• Patent challenges or loss of exclusivity.

What Are TRVI's Competitive Advantages?

• Patent protection for Haduvio and its formulations.
• Clinical trial data demonstrating the efficacy and safety of Haduvio.
• Regulatory exclusivity granted by the FDA upon approval.
• Established relationships with key opinion leaders and healthcare providers.

What Does TRVI Do?

Trevi Therapeutics, Inc., founded in 2011 and headquartered in New Haven, Connecticut, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel treatments for serious neurologically mediated conditions. The company's primary focus is Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing Phase IIb/III clinical trials for the treatment of chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Nalbuphine, the active ingredient in Haduvio, is a mixed opioid agonist-antagonist that has shown promise in alleviating these conditions. Trevi Therapeutics operates under a license agreement with Endo Pharmaceuticals Inc., allowing them to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. This collaboration enhances Trevi's ability to expand its product pipeline and market reach. The company's strategic focus on neurologically mediated conditions positions it within a specialized segment of the biotechnology industry, targeting unmet medical needs with innovative therapeutic solutions. Trevi Therapeutics is committed to advancing Haduvio through clinical development and regulatory approval, with the goal of providing effective treatment options for patients suffering from chronic pruritus and chronic cough associated with IPF.

What Products and Services Does TRVI Offer?

• Develop and commercialize Haduvio, an oral extended-release formulation of nalbuphine.
• Conduct Phase IIb/III clinical trials for Haduvio in chronic pruritus.
• Conduct Phase IIb/III clinical trials for Haduvio in chronic cough in patients with idiopathic pulmonary fibrosis (IPF).
• Focus on treating serious neurologically mediated conditions.
• Maintain a license agreement with Endo Pharmaceuticals Inc. for nalbuphine hydrochloride.
• Seek regulatory approval for Haduvio from the FDA and other regulatory agencies.

How Does TRVI Make Money?

• Develop and patent pharmaceutical products focused on neurologically mediated conditions.
• Conduct clinical trials to demonstrate the safety and efficacy of their drug candidates.
• Seek regulatory approval from agencies like the FDA to commercialize their products.
• Potentially partner with larger pharmaceutical companies for manufacturing, marketing, and distribution.

What Industry Does TRVI Operate In?

Trevi Therapeutics operates within the biotechnology industry, a sector characterized by high innovation and significant regulatory oversight. The market for treatments targeting chronic pruritus and chronic cough in IPF is driven by the increasing prevalence of these conditions and the unmet medical needs of affected patients. The competitive landscape includes companies developing novel therapies for similar indications. Trevi's success depends on its ability to navigate the regulatory approval process and differentiate Haduvio from existing treatments. The biotechnology industry is subject to market volatility, influenced by clinical trial outcomes, regulatory decisions, and technological advancements.

Who Are TRVI's Key Customers?

• Patients suffering from chronic pruritus (chronic itching).
• Patients suffering from chronic cough associated with idiopathic pulmonary fibrosis (IPF).
• Healthcare providers who prescribe treatments for these conditions.
• Pharmaceutical distributors and pharmacies that supply the medication.

Return on equity for Trevi Therapeutics, Inc. stands at -23.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 37.28 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.0%, the inverse of the P/E and a quick read on earnings relative to price.

Trevi Therapeutics, Inc. (TRVI) Valuation Context

Valued at $2.26B, TRVI is classified as a mid-cap stock. Analyst price targets span from $23.00 to $40.00, with a consensus of $29.67. At the current price of $15.91, that implies approximately 86% upside potential. Relative to its peer group, TRVI's quantitative score of 66/100 is below the peer average of 85/100.

Company Profile

Trevi Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New Haven, US. The company is led by CEO Jennifer L. Good. TRVI has traded publicly since 2019.

Trevi Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Trevi Therapeutics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 9.0% above estimates on average.

Wall Street analysts project Trevi Therapeutics, Inc. revenue of about $1.1M for fiscal 2026, with EPS near $-0.48. The estimate reflects 10 contributing analysts.

Over the past six months, Trevi Therapeutics, Inc. insiders filed 5 SEC Form 4 transactions — 0 sales and 5 purchases. On net that is roughly 175K shares acquired (about $2.4M) — insiders putting money in tends to read as conviction.

TRVI Financials

TRVI Latest News

TRVI Analyst Consensus

TRVI MoonshotScore

Trevi Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources